Causes2

  • Cerebral palsy (CP)
  • Traumatic brain injury
  • Epilepsy
  • Congenital abnormality of brain development
Black boxing gloves

Symptoms3

  • Excessive wetness
  • Skin breakdown around the mouth
  • Infection from skin breakdown
  • Dehydration or not enough fluids
  • Foul odor

An estimated 445,000 children under the age of 18 suffer from chronic sialorrhea4,5

Two Principal Types4

Anterior Sialorrhea

forward spillage of saliva from the mouth

Posterior Sialorrhea

backward spillage of saliva from the mouth down airway

A XEOMIN patient with pediatric chronic sialorrhea

Impact on Daily Living6-11

Social
  • Embarrassment
  • Social isolation
  • Stigmatization
Medical
  • Perioral skin breakdown
  • Aspiration pneumonia
  • Choking
  • Dehydration

Complications

Internal Effects
  • Risk of breathing problems
  • Swallowing or feeding difficulties
External Effects
  • Greater risk of infection
  • Skin irritation

Mia Is a 12-year-old Bookworm Who Fills Life with Imagination

The life she's fighting for

Mia has always found herself exploring different worlds with every book she reads. Not only does she love to learn, but she loves sharing these stories with others. Connecting with close friends about their passion for reading and sharing stories they’ve written keeps Mia happy and energized. She gravitates towards heroic characters in books and mirrors their strength, as a force to be reckoned with.

Mia, a patient with pediatric chronic sialorrhea, sitting in a wheelchair talking about XEOMIN

The weigh-in

  • Mia developed chronic sialorrhea due to cerebral palsy
  • Sometimes the drooling can feel embarrassing and interfere with daily things like enjoying a meal or discussing her favorite books with friends

Sparring with chronic sialorrhea

  • For a while, Mia adjusted her life to live with the symptoms of chronic sialorrhea, receiving no treatment
Mia sitting against a black background

Never defeated, Mia and her parents fought back

The Pediatric Portfolio

Watch a pediatric physiatrist discuss the safety and efficacy of XEOMIN for approved pediatric indications

Explore XEOMIN for the treatment of pediatric chronic sialorrhea

See the Data
Worried about waning efficacy?
See the XEOMIN Difference
Learn More Back to Indications
FDA, US Food and Drug Administration.
Change From Baseline in uSFR (Aged 6-17 Years)*
A chart showing the change in pediatric patients, with chronic sialorrhea, from baseline over 16 weeks

Significant improvements were sustained over 16 weeks in the GICS scores

Caregivers' GICS Scores (Aged 6-17 Years)1,12
A chart showing the caregivers' GICS scores for pediatric patients aged 6 to 17, with chronic sialorrhea, over 16 weeks
Parents and caregivers noticed an improvement in their child’s chronic sialorrhea1

Patients who were 2-5 years old showed similar improvement in caregiver GICS scores as patients aged 6-17 years old1,12

A chart showing the caregivers' GICS scores for pediatric patients aged 2 to 5, with chronic sialorrhea, over 16 weeks
See Xeomin Safety
Worried about waning efficacy?
See the XEOMIN Difference
Learn More Back to Indications

FDA, US Food and Drug Administration; uSFR, unstimulated salivary flow rate; GICS, Global Impression of Change Scale.

Common Adverse Reactions

MAIN PHASE1,12

The most frequently reported adverse reaction in patients aged 2-5 years after XEOMIN injections was nasopharyngitis (6%).

OLEX PHASE12

No major differences in adverse reactions across injection cycles were observed.

Most common adverse reactions (incidence ≥1% of patients and greater than placebo)1
Adverse Reactions
Percentage of patients
XEOMIN
(6–17 years, n=148)
Placebo
(6–17 years, n=72)
Bronchitis
1
0
Headache
1
0
Nausea/Vomiting
1
0
Learn about XEOMIN Dosing
Worried about waning efficacy?
See the XEOMIN Difference
Learn More Back to Indications

FDA, US Food and Drug Administration; OLEX, open-label extension.

References

  1. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2023.
  2. Lakraj AA, Moghimi N, Jabbari B. Sialorrhea: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins (Basel). 2013;5(5):1010-1031.
  3. Hockstein NG, Samadi DS, Gendron K, Handler SD. Sialorrhea: a management challenge.  Am Fam Physician. 2004;69(11):2628-2634.
  4. Fairhurst CB, Cockerill H. Management of drooling in children.  Arch Dis Child Educ Pract Ed. 2011;96(1):25-30.
  5. American Academy for Cerebral Palsy and Developmental Medicine. Care pathways: sialorrhea in cerebral palsy. Accessed June 20, 2023. https://www.aacpdm.org/publications/care-pathways/sialorrhea-in-cerebral-palsy
  6. Kalf JG, Smit AM, Bloem BR, Zwarts MJ, Munneke M. Impact of drooling in Parkinson’s disease. J Neurol. 2007;254(9):1227-1232.
  7. Leibner J, Ramjit A, Sedig L, et al. The impact of and the factors associated with drooling in Parkinson’s disease. Parkinsonism Relat Disord. 2010;16(7):475-477.
  8. Ou R, Guo X, Wei Q, et al. Prevalence and clinical correlates of drooling in Parkinson disease: a study on 518 Chinese patients. Parkinsonism Relat Disord. 2015;21(3):211-215.
  9. Schririnzi T, Imbriani P, D’Elia A, Di Lazzaro G, Mercuri NB, Pisani A. Rotigotine may control drooling in patients with Parkinson’s disease: preliminary findings. Clin Neurol Neurosurg. 2017;156:63-65.
  10. Banfi P, Ticozzi N, Lax A, Guidugli GA, Nicolini A. A review of options for treating sialorrhea in amyotrophic lateral sclerosis. Respir Care. 2015;60(3):446-454.
  11. El-Hakim H, Richards S, Thevasagayam MS. Major salivary duct clipping for control problems in developmentally challenged children.  Arch Otolaryngol Head Neck Surg. 2008;134(5):470-474.
  12. Berweck S, Bonikowski M, Kim H, et al. Placebo-controlled clinical trial of incobotulinumtoxinA for sialorrhea in children: SIPEXI. Neurology. 2021;97(14):e1425-e1436.
Back to Top
IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING
WARNING:
DISTANT SPREAD OF TOXIN EFFECT

See full prescribing information for complete BOXED WARNING.

The effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms.

INDICATIONS

XEOMIN® (incobotulinumtoxinA) for injection is indicated for the treatment of:

  • Chronic sialorrhea in patients 2 years of age and older
  • Upper limb spasticity in adults
  • Upper limb spasticity in pediatric patients 2 years of age and older, excluding spasticity caused by cerebral palsy
  • Cervical dystonia in adults
  • Blepharospasm in adults
CONTRAINDICATIONS
  • Known hypersensitivity to any botulinum toxin product or to any of the components in the formulation.
  • Infection at the proposed injection site(s) because it could lead to severe local or disseminated infection.
WARNINGS AND PRECAUTIONS
  • The potency units of XEOMIN are specific to the preparation and assay method used and are not interchangeable with other preparations of botulinum toxin products. Therefore, Units of biological activity of XEOMIN cannot be compared to or converted into Units of any other botulinum toxin products.
  • Serious hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea). If serious and/or immediate hypersensitivity reactions occur, discontinue further injection of XEOMIN and institute appropriate medical therapy immediately. The use of XEOMIN in patients with a known hypersensitivity to any botulinum neurotoxin or to any of the excipients (human albumin, sucrose), could lead to a life-threatening allergic reaction.
  • Treatment with XEOMIN and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. When distant effects occur, additional respiratory muscles may be involved. Patients may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. Dysphagia may persist for several months, which may require use of a feeding tube. Aspiration may result from severe dysphagia [See BOXED WARNING].
  • Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) may be at increased risk for severe dysphagia and respiratory compromise from typical doses of XEOMIN.
  • Caution should be taken when XEOMIN is used where the targeted muscle shows excessive weakness or atrophy.
  • Cervical Dystonia: Treatment with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation. This may result in critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles. There have been post- marketing reports of serious breathing difficulties, including respiratory failure, in patients with cervical dystonia treated with botulinum toxin products. Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles are at greater risk of dysphagia. Limiting the dose injected into the sternocleidomastoid muscle may decrease the occurrence of dysphagia.
  • Blepharospasm: Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation. To decrease the risk for ectropion, XEOMIN should not be injected into the medial lower eyelid area.
  • XEOMIN contains human serum albumin. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been reported for albumin.
ADVERSE REACTIONS

The most commonly observed adverse reactions at rates specified below and greater than placebo are:

  • Chronic Sialorrhea:
    • in adults (≥4% of patients): tooth extraction, dry mouth, diarrhea, and hypertension.
    • in pediatric patients (≥1% of patients): bronchitis, headache, and nausea/vomiting.
  • Upper Limb Spasticity
    • in adults (≥2% of patients): seizure, nasopharyngitis, dry mouth, and upper respiratory tract infection.
    • in pediatric patients (≥3% of patients): nasopharyngitis and bronchitis.
  • Cervical Dystonia in adults (≥5% of patients): dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain.
  • Blepharospasm in adults (≥10% of patients): eyelid ptosis, dry eye, visual impairment, and dry mouth.
DRUG INTERACTIONS

Co-administration of XEOMIN and aminoglycoside or other agents interfering with neuromuscular transmission, (e.g., muscle relaxants), should only be performed with caution as these agents may potentiate the effect of the toxin.

Use of anticholinergic drugs after administration of XEOMIN may potentiate systemic anticholinergic effects.

The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

USE IN PREGNANCY

There are no adequate data on the developmental risk associated with the use of XEOMIN in pregnant women. XEOMIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

PEDIATRIC USE

Safety and effectiveness of XEOMIN in patients less than 18 years of age have not been established for lower limb spasticity, cervical dystonia, or blepharospasm. Safety and effectiveness have been established in pediatric patients 2 to 17 years of age in patients with chronic sialorrhea and upper limb spasticity. A pediatric assessment for XEOMIN in upper limb spasticity demonstrates that XEOMIN is safe and effective in another pediatric population. However, XEOMIN is not approved for such patient population due to marketing exclusivity for another botulinum toxin.